tbuckley/cabot-search huggingface dataset:
PWE-099 Desmoid Tumours in Familial Adenomatous Polyposis: Our Experience
Authors: EG Kane, S Delamere, E Garforth, R Heath, P Rooney
Journal: Gut (2016)

<h3>Introduction</h3> Desmoid tumours are rare, benign, non-metastasising fibromatoses that affect 8–23% of patients with FAP. Desmoid disease poses significant morbidity through local compression and obstruction. There is an increased risk in females, pregnancy, those with germline mutation of the APC gene beyond codon 1399 and previous abdominal surgery. Management requires a balance of chemoprophylaxis and careful surgical intervention. We aimed to evaluate our local investigation and management of patients with FAP and desmoid tumours with respect to published guidance. <h3>Methods</h3> Patients with FAP who are on the colorectal database who were known to have desmoid disease were identified. Data was collected retrospectively from case notes, ICE and PACS systems. Management of each patient was compared to the St Mark’s Polyposis Registry guidance and published literature. <h3>Results</h3> There are 41 patients with FAP in our colorectal database (25 female, 16 male). Eleven patients from eight families were identified as having desmoid disease (six female, five male). Ten of these had desmoid tumours; one only postoperative desmoplastic reaction. The median age at diagnosis was 33 (range 8–49). Of the 10, all had undergone colectomy (five restorative proctocolectomy, three ileorectal anastomosis, two panproctocolectomy (eight prophylactically, two for malignancy). Three patients have had excision of desmoid tumours; all abdominal wall tumours. Six patients have been managed conservatively with observation, chemoprophylaxis and ureteric stenting for managing complications of compression. All patients have been kept under surveillance. One patient died following bowel perforation, one following recurrent bowel obstruction with inoperable mesenteric desmoid disease. Genetic testing was performed on the majority but specific mutational analysis was available for only 67% of patients. 6 of 8 of the patients with mutations in the desmoid region have developed desmoid tumours. <h3>Conclusion</h3> Mortality in our patient group from desmoid disease is higher than that from colorectal cancer and periampullary tumours, in line with national reported data. Prophylactic colectomy has been suggested to increase risk of developing desmoid disease especially with mutations in the desmoid region. Our results show that our patients are being managed appropriately but knowledge of location of germline mutation is strongly advised prior to offering prophylactic colectomy and management of solid desmoid tumours. In those with a higher risk of developing desmoid tumours, there may be an argument to continue endoscopic surveillance for as long as possible. <h3>Reference</h3> 1 Speake, <i>et al</i>. Desmoid tumours in patients with familial adenomatous polyposis and desmoid region adenomatous polyposis coli mutations. <i>Br J Surg</i> 2006;<b>93</b>(Suppl 1):21. <h3>Disclosure of Interest</h3> None Declared
Hepatitis B virus infection and decreased risk of nonalcoholic fatty liver disease: A cohort study
Authors: Eun‐Jeong Joo, Yoosoo Chang, Joon‐Sup Yeom, Seungho Ryu
Journal: Hepatology (2016)

The presence of an association between chronic hepatitis B virus (HBV) infection and fatty liver is controversial. We examined the association between HBV infection and the development of nonalcoholic fatty liver disease (NAFLD). We conducted a cohort study of 83,339 participants without NAFLD at baseline who underwent serologic testing for hepatitis B surface antigen (HBsAg) between 2002 and 2006 and were followed annually or biennially until December 2014. NAFLD was defined as the presence of ultrasonographic fatty liver in the absence of excessive alcohol use or other identifiable causes. We used a parametric Cox model to estimate adjusted hazard ratios with 95% confidence intervals of incident NAFLD. During 484,736.1 person-years of follow-up, 20,200 incident NAFLD cases were identified. In models adjusted for age, sex, year of visit, smoking status, alcohol intake, regular exercise, education level, and body mass index, the adjusted hazard ratio (95% confidence interval) for incident NAFLD comparing HBsAg-positive to HBsAg-negative participants was 0.83 (0.73-0.94). After introducing HBV infection and confounders (including homeostasis model assessment of insulin resistance and metabolic factors) as time-dependent exposures, the association between HBV infection and decreased risk of incident NAFLD was attenuated but persisted. These associations were consistently observed across clinically relevant, prespecified subgroups.In this large cohort of apparently healthy Korean adults, HBsAg seropositivity was associated with lower risk of developing NAFLD, indicating a possible effect of HBV infection on the pathogenesis of NAFLD development. (Hepatology 2017;65:828-835).
Interleukin (IL)-21 in Combination with IL-15 Induces the Differentiation of Human Umbilical Cord Blood CD34−Lineage− Cells into Pseudomature Lytic NK Cells.
Authors: Giuseppina Bonanno, Annabella Procoli, Andrea Mariotti, Maria Corallo, Giovanni Scambia, Luca Pierelli, Giuseppe Leone, Sergio Rutella
Journal: Blood (2007)
Dual Cord Blood Unit (dCBU) Transplantation Increases Short-Term Morbidity, but Has Similar Long-Term Outcome Compared to Matched Unrelated Donor (MUD) Transplantation After Myeloablative Conditioning.
Authors: Matt Kalaycio, Brian J. Bolwell, Lisa Rybicki, Edward Copelan, Hien K. Duong, Brian T. Hill, Robert M. Dean, Brad Pohlman, Steven Andresen, Shawnda Tench, Ronald Sobecks
Journal: Blood (2012)
Long Term Follow up of Patients with Immune Thrombocytopenia Receiving Rituximab
Authors: Khalid Al-Habsi, Murtadha K. Al-Khabori, Muhanna Al-Muslahi, Anil Pathare, Khalil Al Farsi, Mohammed Al Huneini, Sulayma Al Lamki, Salam Alkindi
Journal: Blood (2011)
PTH-001 Underwater Endoscopic Mucosal Resection: The Experience of Two UK Centres
Authors: A Yusuf, N Suzuki, H Htet, N Gautam, S Thomas-Gibson, S Ishaq
Journal: Gut (2016)

<h3>Introduction</h3> Underwater Endoscopic Mucosal Resection (UEMR) is a relatively new technique, which has been developed for endoscopic resection of colonic lesions. In this technique submucosal injection is not required for many of the lesions. We present here the experience of two UK centres. <h3>Methods</h3> All of the UEMR procedures were performed by two experienced interventional endoscopists: NS performed 16 cases at St Mark’s hospital in London, and SI performed 18 cases at Russells Hall Hospital in Dudley. Patient data was collected prospectively. A Hybrid technique, i.e. injection of lifting solution or use of Argon Plasma Coagulation (APC) together with UEMR, was employed if the lesion was traversing a fold/removed in retroflexed position or if there was remnant tissue post resection, respectively. <h3>Results</h3> From May 2015 to February 2016, a total of 34 patients (mean age 64 years, range 35–85, males n = 21) have had UEMR of 35 lesions performed by the two operators. The lesions (mean size 33 mm, range 7–160 mm) were located in right colon (n = 5), transverse colon (n = 2), left colon (n = 9), and rectum (n = 19). Seven of the lesions (20%) were recurrence post previous traditional EMR. The morphology of the lesions were either flat (n = 21) or sessile (n = 14). Hybrid technique was employed as follows: Lifting (n = 14), APC (n = 4), and a combination of lifting and APC (n = 2). Histopathology of the lesions demonstrated low grade dysplasia (n = 29), high grade dysplasia (n = 4), and other (n = 2; One hyperplastic polyp, and one sessile serrated lesion). Complete endoscopic resection (at index procedure) was achieved in 34 out of the 35 lesions (97.1%); a large lesion (160 mm in size), which was crossing over two folds, was resected at two planned sessions. There was no immediate bleeding or perforation, but there was one case of delayed bleeding (2.8%). The procedures, which were performed either with no sedation or analgesia (n = 9), with light sedation and analgesia (n = 18), or with Entonox inhalation as required (n = 7), were well-tolerated with a pain score of zero or one (zero = no pain; one = minimal pain). <h3>Conclusion</h3> In our experience, underwater endoscopic mucosal resection seems to be a safe and a well-tolerated procedure. It can be an alternative to the traditional EMR, which requires either air or CO<sub>2</sub> insufflation, and submucosal injection in all lesions. However, the air or CO<sub>2</sub> insufflation significantly thins the bowel wall during the EMR, and submucosal injection does not only create a potential risk of seeding neoplastic cells into deeper wall layers,<sup>1</sup> but it also prolongs the procedure time. Follow-up data is required to assess the short- and long-term recurrence rate associated with UEMR. <h3>Reference</h3> 1 Binmoeller, KF. <i>J Interv Gastroenterol</i><b>4</b>:<b>4:</b>113–116. <h3>Disclosure of Interest</h3> None Declared
Loss of TGF-β Signaling in Bone Marrow Mesenchymal Progenitors Promotes Adipocyte over Osteoblast Differentiation but Does Not Disrupt the HSC Niche
Authors: Grazia Abou Ezzi, Teerawit Suparkorndej, Bryan Anthony, Jingzhu Zhang, Shilpi Ganguly, Roberto Civitelli, Daniel C. Link
Journal: Blood (2015)
P0605 : Genotype specific variation in the basal core promoter and pre core regions impacts HBeAg levels during immune clearance disease
Authors: J. Bayliss, G. Rosenberg, A. Thompson, A. Gaggar, K. Kitrinos, M. Subramanian, P. Marcellin, E. Gane, H.L Chan, X. Li, D. Colledge, L. Yuen, M. Littlejohn, R. Edwards, K. Jackson, S. Bonanzinga, R. Hammond, S. Bowden, S. Locarnini, P. Revill
Journal: Journal of Hepatology (2015)
Comparison of IgH Gene Rearrangement Configuration between Hairy Cell Leukemia (HCL) and Hairy Cell Leukemia Variant (HCL-v).
Authors: David Gonzalez, Ricardo Morilla, Alison Morilla, Monica Else, Nnenna Osuji, Daniel Catovsky, Claire Dearden, Gareth J. Morgan, Estella Matutes
Journal: Blood (2005)
Clinical Significance of Circulating Ki-67 Protein and Caspase-3 Activity Levels in Chronic Myeloid Leukemia.
Authors: Jean-Marie Bruey, Hagop M. Kantarjian, Zeev Estrov, Wanlong Ma, Chen-Hsiung Yeh, Anthony Sferruzza, Maher Albitar
Journal: Blood (2009)
PWE-119 The Significance of Iron Deficiency in Anaemia in Two Week Referrals for Colorectal Cancer
Authors: S Mashlab, M D’Auria, P Large, W Laing, D Thurston, S Thompson, O Ng, A Acheson, A Banerjea
Journal: Gut (2016)

<h3>Introduction</h3> Anaemia is common and new NICE guidelines (NG12) for suspected colorectal cancer (CRC) broaden the age and type of anaemia qualifying for urgent two week wait (2 WW) referral. Further, NICE now recommend iron therapy (including intravenous iron) for anaemia prior to surgery. Our study examines how anaemia in 2 WW referrals is related to outcome and the potential for iron therapy as treatment. <h3>Methods</h3> Retrospective review of 1000 consecutive patients from 01/12/2014 to 13/07/2015 referred for suspected CRC. Anaemia was defined by WHO (&lt;120g/L women, &lt;130 g/L men), Iron deficiency was defined by BSG (&lt;50ug/L in men and women in presence of inflammatory disease). Data on demographics, referral haemoglobin, MCV, ferritin, referral criteria, investigations and outcome were recorded. <h3>Results</h3> 202/1000 (20.2%) had no haemoglobin at time of referral. 305/798 (38.2%) of patients were anaemic at the time of referral. Only 101/305 (33.1%) had been referred for anaemia and 204/305 (66.8%) for other symptoms. 173/305 (56.7%) had a ferritin recorded. Of 249 anaemic patients who completed investigations 40 (16.1%) had CRC detected. Anaemia was associated with detection of cancer (p &lt; 0.05). If anaemic on referral patients were four and a half times more likely to be diagnosed with CRC (OR4.5 95%CI 2.54–8.11 p =&lt; 0.001). However, low ferritin was not associated with cancer detection (OR1.17 95%CI 0.61–2.27 p = 0.636). 113/305 (37.0%) patients would be suitable for iron therapy and a further 132/305 (43.3%) patients may benefit from assessment of ferritin and subsequent iron therapy if low. <h3>Conclusion</h3> Anaemia (but not iron deficiency) is associated with CRC detection. About half of patients have no recorded ferritin on referral despite anaemia, but identification of iron deficiency is important as it indicates those patients that would likely benefit from iron therapy in anaemia. Nottingham Colorectal Service historically has not insisted on checking for iron deficiency in our 2 WW referral pathway, these results vindicates this approach and are consistent with new NICE guidance. The introduction of faecal occult blood testing in anaemia as per NICE guidance may help to identify those most likely to benefit from investigations. <h3>Disclosure of Interest</h3> None Declared
FLAMSA Conditioning Regimen for Allogeneic Hematopoietic Cell Transplantation in High Risk Myeloid Malignancies Is Also Feasible with Partially Mismatched Donors.
Authors: Michael Stadler, Elke Dammann, Stefanie Buchholz, Bernd Hertenstein, Juergen Krauter, Matthias Eder, Arnold Ganser
Journal: Blood (2007)
SP0192 Disease Impact on Sexuality and Its Management in Rheumatology Care
Authors: S.J. Ryan
Journal: Annals of the Rheumatic Diseases (2016)

This presentation will identify how the symptoms of Inflammatory Arthritis, including joint pain, joint stiffness and fatigue, have the potential to impact on sexuality. Although the issue of sexuality is often neglected in rheumatology care, health professionals can offer advice and support to reduce the effect of the condition on sexuality. Guidance that can be provided within a clinical setting will be discussed. <h3>Disclosure of Interest</h3> None declared
PWE-093 Early Outcomes of Bowelscope Screening (BoSS) Endoscopy &amp; The Resulting Colonoscopies
Authors: A Gaglia, G Fitzgerald, S Hemer, S Stewart, U Duffy, P O’Toole, S Sarkar
Journal: Gut (2016)

<h3>Introduction</h3> Bowel scope screening (BoSS), a 1 off flexible sigmoidoscopy for 55 year olds, has recently been introduced as part of the Bowel Cancer screening in England. The outcomes &amp; pathways of patients have been modelled around the landmark Atkins study and the long term effectiveness of the program will need time to be confirmed. The aim of this study was to review our early experience of the outcomes from BoSS including adenoma detection rate (ADR) and additional findings from colonoscopies following BoSS. <h3>Methods</h3> This was a retrospective study reviewing our BoSS outcomes from the start of BoSS programme from March 2015 to January 2016. This included detailed outcomes of the colonoscopies generated from BoSS. <h3>Results</h3> Over the 10 months of the study 658 BoSS were performed. The ADR was 11%. A total of 29 colonoscopies were generated with a conversion rate of 4.4%. <i>Referral Patterns</i>: When reviewing the referral patterns (21 male patients, 8 females), 7 could be considered inappropriate (24%) either because of over estimation of initial polyp size (n = 3; 10% were actual polyp size below 10 mm) or misdiagnosis of histology (n = 4; 14%&gt; Histology hyperplastic). Of the appropriate referrals, 11 were due to polyps &gt;1 cm (38%)(low risk), 5 (17%) were due to post polypectomy histology -high grade dysplasia and tubovillous (high risk), 4 (14%)were due to polyp &gt;1 cm plus 2 or more adenomas (high risk), one was due to &gt;20 hyperplastic polyps above the rectum and one was due to impossible polypectomy due to poor bowel preparation. <i>Colonoscopic Findings</i>: Of the 7 inappropriate referrals, 6 had only left sided pathology (85%), already diagnosed during BoSS and 1 (15%) had a 4 mm adenoma in the caecum. Of the appropriate referrals 14 of 22 (64%) had only left sided pathology detected. The median size was 6 mm (range 2–45 mm). 8 of 22 (36%) had right sided adenoma; median size 3 mm (range 2–12 mm), of which 4 were referred due to high risk adenomas, 3 due to low risk adenomas, and 1 due to more than 20 hypeplastic polyps above the rectum. <i>Advanced Pathology</i>: Interestingly, the most advanced adenomas in all colonoscopies but one, were the ones visualised at the sigmoidoscopy. One case with a 6 mm tubovillous adenoma in sigmoid had a 12 mm tubulous adenoma in the caecum. 1/22 cases had a 25 mm adenocarcinoma in the rectum. <h3>Conclusion</h3> Our early experience suggests that whilst ADR within the programme is almost double the recommendation, it is important to remain within the pathway in view of the yield of pathology generated which will improve with on-going experience and education. No predictive factor was found for right colon lesions. It is reassuring that the most advanced lesions were the one visualised at the sigmoidoscopy. <h3>Disclosure of Interest</h3> None Declared
ZAP-70 Expression and Stem Cell Transplantation Results in Patients with CLL.
Authors: Neus Villamor, Olga Salamero, Jordi Esteve, Joaquim Carreras, Carol Moreno, Montserrat Rovira, Marta Aymerich, Francesc Bosch, Enric Carreras, Dolors Colomer, Elías Campo, Emili Montserrat
Journal: Blood (2006)
Analysis of Gene Expression in Patients with Acute Graft Versus Host Disease (GVHD) Following Hematopoietic Stem Cell Transplantation (HSCT).
Authors: Laura Tabellini, Ming-Tseh Lin, Wenhong Fan, Era Pogosova-Agadjanyan, Bart Stephens, Lue Ping Zhao, Jerald Radich, John A. Hansen
Journal: Blood (2004)
Infectious Complications In Patients with AL (Immunoglobulin Light Chain) Amyloidosis Undergoing Treatment with High-Dose Melphalan and Autologous Stem-Cell Transplantation (HDM/SCT)
Authors: Sarah Taimur, Claudia Nader, Christine Lloyd-Travaglini, David C Seldin, Vaishali Sanchorawala
Journal: Blood (2011)
PCSM-02SURVIVORSHIP CARE PLANNING IN THE NEURO-ONCOLOGY CLINIC
Authors: Christina Amidei, Jean Arzbaecher, M. Kelly Nicholas
Journal: Neuro-Oncology (2015)

A 2006 Institute of Medicine report recommended that cancer survivorship care planning be implemented into comprehensive care of the patient with cancer. Survivorship care planning is a planned approach to addressing 1) prevention of late effects, 2) surveillance for cancer progression or late effects, 3) intervention for symptoms arising from the cancer or its treatment, and 4) coordination of care amongst healthcare providers. In response to the recommendations, we developed a cancer survivor component of care that was added to the current clinical program and delivered by advanced practice nurses. Survivorship care planning was implemented at completion of the concomitant phase of treatment, upon completion of the adjuvant phase of treatment, and at any time treatment changed. A survivorship care plan template was developed as part of the electronic medical record (EMR) and used to guide survivor discussions. The care plan addressed the four key aspects above with recommendations for interventions related to each aspect. Inclusion of the care plan in the EMR allowed all neuro-oncology team members to provide input into and be able to view the plan collectively; the plan was also shared electronically with the primary provider. Ongoing symptoms were identified using patient self-report data to supplement the examination, and addressed on an individual basis with additional referral to a web-based self-management program. Research about program efficacy is ongoing. Challenges were encountered in identifying reimbursement options and program adaptation to a wide variety of tumor types. A multidisciplinary approach was found to be most helpful in implementing survivorship care planning into comprehensive care for the person with a brain tumor.
TIGAR cooperated with glycolysis to inhibit the apoptosis of leukemia cells and associated with poor prognosis in patients with cytogenetically normal acute myeloid leukemia
Authors: Sixuan Qian, Jianyong Li, Ming Hong, Yu Zhu, Huihui Zhao, Yue Xie, Jiayu Huang, Yun Lian, Yanru Li, Shuai Wang, Jianping Mao, Yaoyu Chen
Journal: Journal of Hematology & Oncology (2016)

Cancer cells show increased glycolysis and take advantage of this metabolic pathway to generate ATP. The TP53-induced glycolysis and apoptosis regulator (TIGAR) inhibits aerobic glycolysis and protects tumor cells from intracellular reactive oxygen species (ROS)-associated apoptosis. However, the function of TIGAR in glycolysis and survival of acute myeloid leukemia cells remains unclear.We analyzed TIGAR expression in cytogenetically normal (CN-) AML patients and the correlations with clinical and biological parameters. In vivo and in vitro, we tested whether glycolysis may induce TIGAR expression and evaluated the combination effect of glycolysis inhibitor and TIGAR knockdown on human leukemia cell proliferation.High TIGAR expression was an independent predictor of poor survival and high incidence of relapse in adult patients with CN-AML. TIGAR also showed high expression in multiple human leukemia cell lines and knockdown of TIGAR activated glycolysis through PFKFB3 upregulation in human leukemia cells. Knockdown of TIGAR inhibited the proliferation of human leukemia cells and sensitized leukemia cells to glycolysis inhibitor both in vitro and in vivo. Furthermore, TIGAR knockdown in combination with glycolysis inhibitor 2-DG led leukemia cells to apoptosis. In addition, the p53 activator Nutlin-3α showed a significant combinational effect with TIGAR knockdown in leukemia cells. However, TIGAR expression and its anti-apoptotic effects were uncoupled from overexpression of exogenous p53 in leukemia cells.TIGAR might be a predictor of poor survival and high incidence of relapse in AML patients, and the combination of TIGAR inhibitors with anti-glycolytic agents may be novel therapies for the future clinical use in AML patients.
Indoleamine 2,3-Dioxygenase and Peripheral Tolerance to Exogenous Factor VIII: A Multi-Centre Pilot Study
Authors: Davide Matino, Alfonso Iorio, Marco Gargaro, Giuseppe Tagariello, Matteo Luciani, Giovanni Di Minno, Antonio Coppola, Leonardo Di Gennaro, Paolo Puccetti, Francesca Fallarino
Journal: Blood (2011)
DOCK180, a New Surrogate Marker to Distinguish CD34 Positive Acute Leukemia Cells from CD34 Positive Normal Hematopoietic Stem/Progenitor Cells.
Authors: Mitsufumi Nishio, Kohki Kumano, Katsuya Fujimoto, Tomoyuki Endo, Satoshi Yamamoto, Akio Shigematsu, Takeshi Kondo, Junji Tanaka, Satoshi Hashino, Masahiro Imamura, Hiroshi Nishihara, Norihiro Sato, Takao Koike
Journal: Blood (2008)
Programmed Death-1 Ligand Is Uniformly Expressed On Primary Mediastinal Diffuse Large B-Cell Lymphoma Cells with No Influence On Patient Survival.
Authors: Vit Prochazka, Tomas Papajik, Patrik Flodr, Pavla Latalova, Zuzana Prouzova, Radka Nedomova, Marie Jarosova, Vladimir Divoky, Karel Indrak
Journal: Blood (2012)
Molecular Characterization and Drug-Sensitivity of Pan Histone Deacetylase Inhibitor Resistant Human Acute Myeloid Leukemia Cells.
Authors: Warren Fiskus, Rekha Rao, Pravina Fernandez, Bryan Herger, Yonghua Yang, Jianguang Chen, Yongchao Wang, Aditya Mandawat, Pearl Lee, Peter Atadja, Kapil Bhalla
Journal: Blood (2007)
Constitutive Activation of p38 MAPK in Myeloma Cells Contributes to Myeloma-Induced Osteolytic Bone Lesions.
Authors: Jing Yang, Yabing Cao, Yuhuan Zheng, Sungyoul Hong, Haiyan Li, Jianfei Qian, Jairo A. Matthews, Michael Wang, Larry W. Kwak, Qing Yi
Journal: Blood (2009)
Microrna-17~92 Cluster Upregulates NF-KB Activity Via Suppressing Multiple NF-KB Negative Regulators Mediating Ubiquitination
Authors: Xianhuo Wang, Huaqing Wang, Chengfeng Bi, Xiaoyan Zhang, Xin Huang, Xuan Zhang, Javeed Iqbal, George W Wright, Louis M Staudt, Wing C Chan, Timothy W McKeithan, Ping Wang, Huilai Zhang, Kai Fu
Journal: Blood (2015)
Elevated Tricuspid Regurgitation Jet Velocity in Patients with Sickling and Non-Sickling Hemolytic Anemias: Prevalence and Correlates
Authors: Amber M. Yates, Vijay Joshi, Kerri Nottage, Matthew P. Smeltzer, Guolian Kang, Devi Govindaswamy, Jola Dowdy, Alyssa Cotton, Russell E. Ware, Jane S. Hankins
Journal: Blood (2014)